Australia's most trusted
source of pharma news
Monday, 24 November 2025
Posted 24 November 2025 PM
The TGA has approved Blenrep, GSK’s ‘Trojan Horse’ antibody drug conjugate for multiple myeloma.
A first-in-class anti-BCMA (B-cell maturation antigen) therapy, Blenrep targets and attaches to myeloma cells before killing them from the inside. The antibody also helps the body’s immune system recognise and clear cancer cells.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.